Opinions
Robert McWhirter
XORTX Therapeutics
XRX-CN
RISKY
Jan 05, 2021
Recently it's jumped from 10 to 17 cents/share. Reason: Covid attacks major organs (lungs, kidneys) and those with gout are particularly vulnerable; XRX has drugs to treat kidneys and uric acid (high levels lead to gout). XRX has two drugs going into phase-3 drug trials. He likes XRX a lot, but it's highly speculative though. XRX could out-license with one of three companies on a share-revenue basis.
N/A
Stock price when the opinion was issued
biotechnology
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
Advertising